Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 4
2020 3
2021 1
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.
Palmer DC, Webber BR, Patel Y, Johnson MJ, Kariya CM, Lahr WS, Parkhurst MR, Gartner JJ, Prickett TD, Lowery FJ, Kishton RJ, Gurusamy D, Franco Z, Vodnala SK, Diers MD, Wolf NK, Slipek NJ, McKenna DH, Sumstad D, Viney L, Henley T, Bürckstümmer T, Baker O, Hu Y, Yan C, Meerzaman D, Padhan K, Lo W, Malekzadeh P, Jia L, Deniger DC, Patel SJ, Robbins PF, McIvor RS, Choudhry M, Rosenberg SA, Moriarity BS, Restifo NP. Palmer DC, et al. Among authors: slipek nj. Med. 2022 Oct 14;3(10):682-704.e8. doi: 10.1016/j.medj.2022.07.008. Epub 2022 Aug 24. Med. 2022. PMID: 36007524 Free article.
SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.
Smeester BA, Slipek NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, Crosby MR, Draper GM, Becklin KL, Rahrmann EP, McCarthy JB, Odde DJ, Wood DK, Largaespada DA, Moriarity BS. Smeester BA, et al. Among authors: slipek nj. Oncogene. 2020 Jan;39(5):1049-1062. doi: 10.1038/s41388-019-1041-x. Epub 2019 Oct 3. Oncogene. 2020. PMID: 31582836
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.
Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BA, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS. Webber BR, et al. Among authors: slipek nj. Nat Commun. 2019 Dec 6;10(1):5659. doi: 10.1038/s41467-019-13778-y. Nat Commun. 2019. PMID: 31811147 Free PMC article.
CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells.
Kluesner MG, Lahr WS, Lonetree CL, Smeester BA, Qiu X, Slipek NJ, Claudio Vázquez PN, Pitzen SP, Pomeroy EJ, Vignes MJ, Lee SC, Bingea SP, Andrew AA, Webber BR, Moriarity BS. Kluesner MG, et al. Among authors: slipek nj. Nat Commun. 2021 Apr 23;12(1):2437. doi: 10.1038/s41467-021-22009-2. Nat Commun. 2021. PMID: 33893286 Free PMC article.
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby MR, Wang M, Rahrmann EP, Moriarity BS, Largaespada DA. Smeester BA, et al. Among authors: slipek nj. Bone. 2020 Jul;136:115353. doi: 10.1016/j.bone.2020.115353. Epub 2020 Apr 3. Bone. 2020. PMID: 32251854
Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma.
Smeester BA, Draper GM, Slipek NJ, Larsson AT, Stratton N, Pomeroy EJ, Becklin KL, Yamamoto K, Williams KB, Laoharawee K, Peterson JJ, Abrahante JE, Rathe SK, Mills LJ, Crosby MR, Hudson WA, Rahrmann EP, Largaespada DA, Moriarity BS. Smeester BA, et al. Among authors: slipek nj. Mol Cancer Ther. 2020 Dec;19(12):2528-2541. doi: 10.1158/1535-7163.MCT-20-0369. Epub 2020 Sep 30. Mol Cancer Ther. 2020. PMID: 32999043 Free PMC article.